Author: Dr Anika Schröter
The development of RNA-based drugs has increased within the past years and is a promising field of research in the pharmaceutical industry. It is transforming the industry and will offer new hope for patients with unmet medical needs.
RNA-based drugs have several advantages over conventional drugs, such as the ability to target previously undruggable pathways, the rapid and cost-effective development, and the potential for personalized medicine. However, RNA-based drugs also face some challenges, such as the stability, delivery, and safety of the RNA molecules.
This whitepaper informs about the challenges with the 'standard' non-clinical program for different RNA-based drugs, focusing on safety evaluation.
Download now the white paper 'Non-clinical aspects of RNA-based drug development'.
We hope you enjoy reading it!
This online webcast series provides a concise update on the EU Pharmaceutical Package. Across five two-hour modules, you learn about key regulatory changes, revised authorisation and protection rules, new obligations for managing shortages, and developments in environmental risk assessment. Gain practical guidance to adapt internal processes and responsibilities to the upcoming framework.
Stay informed with updates from our global and local experts, who will provide the latest regulatory and legislative insights every two months. In 2026, topics will include CMC documentation, regulatory intelligence, regulatory pathways in Africa, enrichment of PMS product data, global regulatory reliance models and ePI.
Regulatory expectations regarding risk management for pharmaceuticals in (emerging) markets often contend with the stringent standards set by the EU/ICH regions. Join us in six consecutive webcasts to gain insights into local pharmacovigilance systems in different countries and regions, and learn how to integrate them into your global PV system while maintaining a clear overview!
The seminar covers essential topics such as stakeholder identification, effective meeting preparation, and legally compliant collaboration. Tailored for Medical Science Liaisons (MSLs) and Medical Affairs teams, the seminar equips you to gain real insights from KOLs, overcome challenging situations, and elevate patient outcomes.
The event will cover recent updates and practical implications of the EU pharmaceutical legislation, the application of AI in RA, and the new EU Variation regulation. Additionally, it will address the latest developments in quality (draft) guidelines: ICH M13A + M13B, ICH M4Q(R2), an update on the ongoing discussions on nitrosamine contaminations, and the revision of PACMP, Lifecycle Management.
Overview of RA outsourcing & vendor oversight: risk-based vendor selection, governance and compliance controls. Practical and compact in just half a day
Learn how artificial intelligence is transforming the pharmaceutical industry in Europe. This foundation course covers AI concepts, key use cases, EU AI Act and GDPR essentials, GxP implications and practical steps to implement AI safely and at scale.
Radiopharmaceuticals are facing a pivotal regulatory moment. This seminar brings together experts from a regulatory authority, a CDMO, and a sponsoring company to provide practical, up-to-date guidance on CMC and quality requirements under current and forthcoming EU standards.
Our experienced speakers will help you prepare for all the challenges that supervisory boards face. Including Fit & Proper requirements for supervisory board members according to § 25c KWG, new BaFin circular on FAP (fit and proper) of October 22, 2025.
Our experienced speakers will help you prepare for all the challenges facing board members in German banks. Including Fit & Proper requirements for management board members according to § 25c KWG, new BaFin circular on FAP (fit and proper) of October 22, 2025.
This seminar covers the key drivers of digital transformation in Regulatory Operations - from data quality and AI-driven automation to IDMP, eCTD 4.0, and ePI. Across two half-day sessions, you will gain practical strategies and discuss real-world use cases with experienced practitioners.
